Compare · MDGS vs WST
MDGS vs WST
Side-by-side comparison of Medigus Ltd. (MDGS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDGS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $29.12B, about 884.6x MDGS ($32.9M).
- WST has hit the wire 4 times in the past 4 weeks while MDGS has been quiet.
- WST has more recent analyst coverage (15 ratings vs 0 for MDGS).
- Company
- Medigus Ltd.
- West Pharmaceutical Services Inc.
- Price
- $2.48-1.98%
- $306.12-1.10%
- Market cap
- $32.9M
- $29.12B
- 1M return
- -
- +23.98%
- 1Y return
- -
- +41.67%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 15
Medigus Ltd.
Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools with direct visualization technology in the United States, the United Kingdom, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; develops and commercializes online and offline event planning software, as well as ticketing solutions; and operates online stores for the sale of various consumer products on the Amazon online marketplace. The company was incorporated in 1999 and is headquartered in Omer, Israel.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest MDGS
- Xylo Technologies: Viewbix Shares to Begin Trading on Nasdaq
- Xylo Technologies: Charging Robotics Successfully Installs Wireless EV Charging System in Automatic Parking Facility
- Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment
- Xylo Technologies: Revoltz Launches Commercial Phase of PORTO EV in Israel with First 50 Vehicles Delivered to Exclusive Distributor
- Xylo Technologies: Revoltz Receives Israeli Standards Institute Approval for PORTO EV Micro Vehicle
- Xylo Technologies: ParaZero Received Order from a Leading Tier-One Defense Company for 50 Drone Safety Systems
- Xylo Technologies: Revoltz to Launch an Innovative Three-Wheel Electric Cargo Bike for European and UK Markets
- Xylo Technologies Announces Plan to Implement ADS Ratio Change
- Xylo Technologies: Charging Robotics Lands Commercial Order for EV Wireless Charging Systems in Automatic Car Parks
- Xylo Technologies: Charging Robotics Secures First Commercial Order for EV Wireless Charging Systems in Automatic Car Parks
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Reports First-Quarter 2026 Results
- West to Host First-Quarter 2026 Conference Call
- SEC Form 4 filed by Haugen Janet Brutschea
- West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- SEC Form DEFA14A filed by West Pharmaceutical Services Inc.
- SEC Form DEF 14A filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits